Oncology & Immunology Innovation Partnering & Licensing Summit

The Oncology & Immunology Innovation Partnering & Licensing Summit 2026 will take place on 9–10 September 2026 in Boston, Massachusetts, USA. The event is designed to accelerate licensing, partnering and co-development opportunities across oncology and autoimmune disease by bringing together pharmaceutical business development leaders, innovative biotechnology companies and investors on a focused networking and deal-making platform.

The summit is specifically tailored for organisations developing technologies and therapeutic modalities such as antibody-drug conjugates (ADCs), T-cell engagers (TCEs), bispecific antibodies (BsAbs), targeted protein degraders (TPDs) and in vivo CAR-T therapies. Through a combination of strategic discussions, one-to-one partnering meetings, investor engagement sessions and industry-led presentations, participants can gain insights into partnership expectations, asset differentiation, licensing opportunities and future investment priorities.

A key feature of the event is its structured partnering framework, which includes a dedicated one-to-one partnering system, pharma and investor icebreaker discussions, networking roundtables, presentation opportunities and organized matchmaking. The programme is designed to help biotechnology companies understand what pharmaceutical companies and investors are seeking in emerging assets, technologies and data packages while enabling business development teams to connect directly with decision-makers.

The summit is strategically positioned between BIO and JPM and is intended to provide a highly focused environment with favorable pharma-to-biotech engagement. Event statistics highlight a 1:5 ratio of biotech companies to pharma and investors, more than 24% meeting acceptance rates on the partnering platform, structured networking opportunities and significant participation from pharmaceutical and investment organizations.